Skip to main content
    B

    Biogen Inc (BIIB)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NASDAQ

    $251.65
    -1.75 (-0.69%)

    Market Cap: $37.46B

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Biogen Inc (BIIB) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Biogen (BIIB) trades at 21.4x trailing earnings and 3.6x sales. Its P/E of 21.4x is above its 5-year median of 12.5x. Its forward P/E is 16.4x. The median P/E across 8 similar companies is 14.5x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 30.5% higher over the next year. Its free cash flow yield is 5.6%.

    MultipleValue
    P/E (trailing)21.4x
    Forward P/E16.4x
    Price to sales3.6x
    Price to book2.0x
    EV/EBITDA23.0x
    Price to FCF18.0x
    EV/FCF21.0x
    PEG3.5
    FCF yield5.6%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/E is 72.6% above 12.4x, its P/S is 5.9% above 3.4x and its P/B is 37.5% below 3.2x.

    MultipleCurrent5-year median10-year median
    P/E21.4x12.5x12.4x
    P/S3.6x3.1x3.4x
    P/B2.0x2.1x3.2x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/E ranged from 7.5x in 2020 to 17.2x in 2023.

    Year endPriceP/EP/SP/B
    2025$175.9911.5x2.6x1.4x
    2024$152.929.3x2.3x1.3x
    2023$258.7717.2x3.8x2.5x
    2022$276.9215.7x4.0x3.0x
    2021$239.9212.5x3.3x3.2x
    2020$244.867.5x2.9x3.5x
    2019$296.738.8x3.9x4.0x
    2018$300.9211.5x4.6x4.6x
    2017$318.5714.6x5.5x5.4x
    2016$283.5814.0x5.4x5.1x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewFairly valued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About BIIB

    What is BIIB's forward P/E ratio?

    Biogen has a forward P/E ratio of 16.4x.

    Is BIIB stock overvalued?

    GNG's valuation label for BIIB is Fairly valued. Its P/E of 21.4x compares with a median of 14.5x across 8 similar companies.

    What is BIIB's price to sales ratio?

    Biogen has a price to sales ratio of 3.6x.

    What is Biogen's average P/E ratio over 5 years?

    Biogen's median P/E over the last 5 years is 12.5x, from 60 month-end values through Oct 2026.

    What is BIIB's PEG ratio?

    Biogen has a PEG ratio of 3.5.